As of June 21, 2025, Chiasma Inc (CHMA) reports a Gross Margin of 94.59%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Chiasma Inc's Gross Margin to Peers
To better understand Chiasma Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Chiasma Inc (CHMA) | 94.59% |
| Onconova Therapeutics Inc (ONTX) | 7775.20% |
| Avenue Therapeutics Inc (ATXI) | 7775.20% |
| Royalty Pharma PLC (RPRX) | 7775.20% |
| Processa Pharmaceuticals Inc (PCSA) | 100.00% |
| Cardiol Therapeutics Inc (CRDL.TO) | 100.00% |
Compared to its competitors, Chiasma Inc's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.